Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2005-08-02
2005-08-02
Harris, Alana M. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S193100, C424S198100, C424S085100, C424S085200, C424S085400, C424S085700, C514S002600, C530S402000, C530S399000
Reexamination Certificate
active
06923966
ABSTRACT:
Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
REFERENCES:
patent: 4492537 (1985-01-01), Awerkamp
patent: 4530901 (1985-07-01), Weissmann
patent: 4695623 (1987-09-01), Stabinsky
patent: 4766106 (1988-08-01), Katre et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 4917888 (1990-04-01), Katre et al.
patent: 5382427 (1995-01-01), Plunkett et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5762923 (1998-06-01), Gross et al.
patent: 5766582 (1998-06-01), Yuen et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5776897 (1998-07-01), Lewis et al.
patent: 5908621 (1999-06-01), Glue et al.
patent: 5951974 (1999-09-01), Gilbert et al.
patent: 5985263 (1999-11-01), Lee et al.
patent: 6362162 (2002-03-01), Rybak et al.
patent: 2001/0053548 (2001-12-01), Rybak et al.
patent: 0 510 356 (1992-10-01), None
patent: 0 593 868 (1994-04-01), None
patent: 0 236 987 (1994-12-01), None
patent: 0 809 996 (1997-12-01), None
patent: WO95/13090 (1995-05-01), None
patent: WO98/48840 (1998-05-01), None
patent: WO 99/48535 (1999-09-01), None
Bruno, René, et al., “Population Pharmacokinetics/Pharmacodynamics of Docetaxel in Phase II Studies in Patients with Cancer,”Journal of Clinical Oncology16(1):187-96 (1998).
Calvert, A.H., et al., “Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function,”Journal of Clinical Oncology7(11):1748-56 (1989).
Eisenhauer, Elizabeth A., et al., “The Taxoids, Comparative Clinical Pharmacology and Therapeutic Potential,”Drugs55(1):5-30 (1998).
Eksborg, Steffan, et al., “Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite-a comparison of bolus versus 2 h infusion during a 3 day course,”Anti-Cancer Drugs8:42-7 (1997).
Forastiere, Arlene A., et al., “Pharmacokinetic and Toxicity Evaluation of Five-Day Continuous Infusion versus Intermittent Bolus cis -Diamminedichloroplatinum(II) in Head and Neck Cancer Patients,”Cancer Research48:3869-3874 (1988).
Gandhi, Varsha, et al., “Compound GW 506U78 in Refractory Hematologic Malignancies: Relationship Between Cellular Pharmacokinetics and Clinical Response,”Journal of Clinical Oncology16(11):3607-15 (1998).
Rodman, John H., et al., “Clinical Pharmacodynamics of Continuous Infusion Teniposide: Systemic Exposure as a Determinant of Response in a Phase I Trial,”Journal of Clinical Oncology5(7):1007-1014 (1987).
Shalinsky, David R., et al., “Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations,”Investigational New Drugs16:303-13 (1999).
Takitani, Kimitaka, et al., “4-Oxo Retinoic Acid for Refractory Acute Promyelocytic Leukemia in Children with All-Trans Retinoic Acid Therapy,”J. Nutr. Sci. Vitaminol.41:493-98 (1995).
Kantarjian et al., “Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options,” Blood 87:8 pp. 3069-3081, Apr. 15, 1996.
Hehlman et al., “Randomized Comparison of Interferon-α With Busulfan and Hydroxyurea in Chromic Myelogenous Leukemia,” Blood 84:12 pp. 4064-4077, Dec. 15, 1994.
Kantarjian et al., “Chronic Myelogenous Leukemia: A Concise Update,” Blood 82:3 pp. 691-703, Aug. 1, 1993.
Nicolaou et al., “Total Synthesis of Taxol. 1. Retrosynthesis, Degradation, and Reconstitution,” J. Am. Chem. Soc. 117 pp. 624-633, 1995.
Ozer et al., “Prolonged Subcutaneous Administration of Recombinant α2b Interferon in Patients with Previously Untreated Philadelphia Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia: Effect on Remission Duration and Survival: Cancer and Leukemia Group B Study 8583,” Blooc 82:10 pp. 2975-2984, Nov. 15, 1993.
Ohnishi et al., “A Randomized Trial Comparing Interferon-α With Busulfan for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase,” Blood 86:3 pp. 906-916, Aug. 1, 1995.
Creagon et al., “Randomized, Surgical Adjuvent Clinical Trial of Recombinant Interferon Alfa-2a in Selected Patients With Malignant Melanoma,” Journal of Clinical Oncology, 13:13 pp. 2776-2783 Nov. 1995.
Bergmann et al., “Daily Alternating Administration of High-Dose Alph-2b-Interferon and Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer,” Cancer 72:5, pp. 1735-1742 Sep. 1, 1993.
Umeda et al., “Phase II Study of Alpha Interferon on Renal Cell Carcinoma,” Cancer 58:1231-1235, Sep. 15, 1986.
Sokal et al., “Preferentiall Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia,” Cancer 59:197-202, Jan. 1, 1987.
Fleming et al., “One-Sample Multiplel Testing Procedure for Phase II Clinical Trials,” Biometrics 38:143-151 Mar. 1982.
Rosenberg, et al., “Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients,” Ann. Surg. 210:4 pp. 474-485, 1989.
Kantarjian et al., “Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic Response to Interferon-α Therapy,” Ann Intern Med. 122:254-261, 1995.
Talpaz et al., “Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenouos Leukemia,” Annals of Internal Medicine, 114:7 Apr. 1, 1991.
Négrier et al., “Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinoma,” Journal of Immunotherapy, 17:62-68 1995.
Goldman, “Optimizing Treatment for Chronic Myeloid Leukeemia,” The New England Journal of Medicine, 337:4, pp. 270-271, Jul. 24, 1997.
Guilhot, et al., “Interferon Alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia,” The New England Journal of Medicine, 337:4 pp. 223-229, 1997.
The Italian Cooperative Study Group on Chronic Myeloid Leukemia, “Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia,” The New England Journal of Medicine, 330:12 pp. 820-825, Mar. 24, 1994.
Atzpodien et al., “Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma,” Journal of Clinical Oncology, 13:2 pp. 497-501 Feb. 1995.
Kirkwood et al., “Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,” Journal of Clinical Oncology, 14: 1 pp. 7-17, Jan. 1996.
Atzpodien et al., “Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies,” The Lancet, 335 pp. 1509-1512, 1990.
Alfonso Gennaro, “Antineoplastic and Immunoactive Drugs,” Remington's 18thEd., 1990.
Bukowski, “Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors,” American Society of Clinical Oncology, 1999 Abstract.
Deprés-Brummer et al., “A Phase II Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC),” American Society of Clinical Oncology, Abstract No. 628, 15:248, Mar. 1996.
Escudier et al., “The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC),” American Society of Clinical Oncology, Abstract No. 629, 15:248, Mar. 1996.
Gitlitz et al., “Fluoropyrimidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma: The UCLA Kidney Cancer Program,” American Soc
Rose Esther Helen
Rybak Mary Ellen
Biro Michael G.
Davis Michael D.
Harris Alana M.
Henderson Melodie W.
Holleran Anne L.
LandOfFree
Melanoma therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Melanoma therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanoma therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3443960